EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment

Andrea Fava iD, Catriona A Wagner, Carla J Guthridge, Susan Macwana, Wade DeJager, Melissa E Munroe, Peter Izmirly, H Michael Belmont, Betty Diamond, Anne Davidson iD, Paul J Utz, Michael H Weisman und 15 weitere

Arthritis Care & Research · 2026-04 · 78 (4) · 520-527

DOI: 10.1002/acr.25652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 03.12.2025. Verfasst von Andrea Fava und 26 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University, Baltimore, Maryland. Hauptthemen laut MEDLINE: Lupus Nephritis, Kidney. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, NCRR NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response.

Methods

Patients with systemic lupus erythematosus (SLE) (n = 268) undergoing clinically indicated kidney biopsies (urine protein/creatinine ratio [UPCR] ≥ 0.5) were recruited through the AMP Rheumatoid Arthritis and SLE Network. Serum was collected at biopsy and 3‐, 6‐, and 12‐month postbiopsy, alongside samples from 22 healthy controls. Concentrations of 66 immune mediators were quantified using xMAP multiplex assays, and (TACE) measured by enzyme‐linked immunosorbent assay. Seven mediators with >95% values below detection limits were excluded from analyses. Bootstrapped least absolute shrinkage and selection operator (LASSO) regression identified proliferative LN (class III/IV ± V) predictors from baseline mediators. Associations with 12‐month treatment response (complete/partial vs no response) were tested using three‐month changes in LASSO‐selected mediators and UPCR via logistic regression. Molecular clustering of mediator profiles was performed to identify LN subgroups.

Results

Proliferative patients with LN (class [III or IV] ± V; n = 160) displayed a distinct mediator profile compared with nonproliferative LN (class I, II, or V; n = 96). LASSO regression identified 20 mediators predictive of proliferative LN (areas under the curve, 0.82; 95% confidence interval [CI], 0.81–0.91), including elevated syndecan‐1, tumor necrosis factor receptor type I, tumor necrosis factor receptor type II, and vascular cell adhesion molecule 1 (VCAM‐1), as well as decreased CCL3//macrophage inflammatory protein 1α, CD40 ligand, and interleukin‐5 levels. Among proliferative patients with LN, 3‐month reductions in syndecan‐1 and VCAM‐1, mediators associated with intrarenal LN activity and/or chronicity, predicted the 12‐month treatment response. A model incorporated these reductions and a decline in UPCR‐predicted treatment response in proliferative LN (0.90; 95% CI, 0.82–0.98). Molecular clustering revealed four distinct LN subgroups with unique soluble mediator signatures and clinical features not captured by histology alone.

Conclusion

Serum soluble mediators, particularly syndecan‐1 and VCAM‐1, reflect LN histologic activity, and early decreases predict treatment response, supporting their potential use as noninvasive longitudinal biomarkers. The substantial heterogeneity within LN highlights the potential for biomarker‐guided reclassification to advance precision medicine approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisKidneyHumansFemaleMaleAdultBiomarkersMiddle AgedTreatment OutcomeBiopsyImmunosuppressive AgentsCase-Control Studies

Substanzen

BiomarkersImmunosuppressive Agents

Autor:innen und Institutionen

  • Johns Hopkins University, Baltimore, Maryland.
  • Oklahoma Medical Research Foundation, Oklahoma City.
  • New York University Grossman School of Medicine, New York.
  • Feinstein Institutes for Medical Research, Manhasset, New York.
  • Stanford University School of Medicine, Stanford, California.
  • Cedars-Sinai Medical Center, Los Angeles, California.

ORCID-Profile: Andrea Fava, Anne Davidson, Philip M Carlucci, Chaim Putterman, Jennifer L Barnas, Richard A Furie, Deepak A Rao, Michelle Petri, Jill Buyon, Judith A James

Förderung

  • NIAMS NIH HHS
  • NCRR NIH HHS
  • NIDDK NIH HHS
  • Lupus Foundation of America
  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Fava, A., Wagner, C. A., Guthridge, C. J., Macwana, S., DeJager, W., Munroe, M. E., Izmirly, P., Belmont, H. M., Diamond, B., Davidson, A., Utz, P. J., Weisman, M. H., Carlucci, P. M., Dall'Era, M., Kalunian, K., Putterman, C., Anolik, J., Barnas, J. L., Wofsy, D., …, & James, J. A. (2026). Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment. Arthritis Care & Research, 78(4), 520-527. https://doi.org/10.1002/acr.25652

Vancouver

Fava A, Wagner CA, Guthridge CJ, Macwana S, DeJager W, Munroe ME, et al. Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment. Arthritis Care & Research. 2026;78(4):520-527. doi:10.1002/acr.25652

BibTeX
@article{Fava2026,
  author = {Fava, Andrea and Wagner, Catriona A and Guthridge, Carla J and Macwana, Susan and DeJager, Wade and Munroe, Melissa E and Izmirly, Peter and Belmont, H Michael and Diamond, Betty and Davidson, Anne and Utz, Paul J and Weisman, Michael H and Carlucci, Philip M and Dall'Era, Maria and Kalunian, Kenneth and Putterman, Chaim and Anolik, Jennifer and Barnas, Jennifer L and Wofsy, David and Kamen, Diane and Furie, Richard A and Rao, Deepak A and Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus Network, Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus Network and Petri, Michelle and Guthridge, Joel M and Buyon, Jill and James, Judith A},
  title = {Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment},
  journal = {Arthritis Care & Research},
  year = {2026},
  volume = {78},
  number = {4},
  pages = {520--527},
  doi = {10.1002/acr.25652}
}
Kostenlos starten →